Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis

The study examined the effects of atorvastatin on cardiometabolic risk factors in 58 women, divided into two groups: those with euthyroid autoimmune thyroiditis (group A, n=29) and those without thyroid pathology (group B, n=29). Over 6 months, atorvastatin improved certain cardiometabolic parameters in both groups, but women with thyroiditis experienced less benefit. Specifically, reductions in high-sensitivity C-reactive protein (hsCRP) and homocysteine were less pronounced in group A, and only group B showed decreases in uric acid and fibrinogen levels and an increase in 25-hydroxyvitamin D. Additionally, atorvastatin worsened insulin sensitivity in women with thyroiditis. The study concluded that women with Hashimoto’s thyroiditis might be less suitable candidates for atorvastatin due to partial resistance to its effects, suggesting the need for tailored treatments. However, the small sample size and short duration of the study limited the strength of the findings.